-
Mashup Score: 0Boehringer Ingelheim launches phase 2 study of oral therapy for diabetic macular edema - 4 hour(s) ago
Boehringer Ingelheim initiates the THULITE study, exploring an oral treatment for diabetic macular edema.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 0LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada - 12 hour(s) ago
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
LENZ Therapeutics and Laboratoires Théa have announced a license and commercialization agreement for Théa to register and commercialize LNZ100 for the treatment of presbyopia in Canada. https://t.co/sq2YxFpnVX
-
-
Mashup Score: 2
The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
4D Molecular Therapeutics has announced it is accelerating its 4D-150 4FRONT phase 3 program in wet age-related macular degeneration (wet AMD) and will lay off approximately 25% of staff. https://t.co/1hOnyJRted
-
-
Mashup Score: 2
Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable implant injected intravitreally every 6 months.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Two phase 2a clinical trials showed positive results for the PER-001 intravitreal implant as the first disease-modifying treatment for glaucoma and diabetic retinopathy (DR), according to a press release issued by Perfuse Therapeutics. https://t.co/GLEokXBoKo
-
-
Mashup Score: 5Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD - 2 day(s) ago
LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Alcon is continuing its trend of acquisitions in 2025 with the recent announcement that the company will acquire LumiThera, Inc. and its photobiomodulation (PBM) device for the treatment of early and intermediate dry age-related macular degeneration (AMD) https://t.co/Gjt8KOMzcf
-
-
Mashup Score: 0Expanding access, enhancing research: The evolving landscape of ophthalmic clinical trials - 16 day(s) ago
Changing demographics and increasing trial complexity present challenges and opportunities.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Expanding access, enhancing research: The evolving landscape of ophthalmic clinical trials. Changing demographics and increasing trial complexity present challenges and opportunities. https://t.co/vuCAP3KMHJ
-
-
Mashup Score: 1
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
The challenges and pressures of clinical practice have physicians looking for ways to increase their office’s efficiency, an attempt to meet the sweet spot that balances the results obtained with the effort expended https://t.co/YqPDiGom2m
-
-
Mashup Score: 7Targeted therapies improve care for Demodex blepharitis and OSD - 17 day(s) ago
Timely diagnosis and personalized treatment are key to improving visual outcomes.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
A recent Ophthalmology Times Case-Based Roundtable® tackled the topic of treating Demodex blepharitis and ocular surface disease (OSD) to maximize visual outcomes. https://t.co/cRH8xPf7nv
-
-
Mashup Score: 5Ophthalmology Times: May/June 2025 - 17 day(s) ago
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
In the latest issue of Ophthalmology Times, read about pathways helping patients and providers move in sync. Also, learn about a new tool in the uveitis armamentarium and uncover insights into USH2A target end points. Read here: https://t.co/O4VfQJsOHj #NewIssue #Uveitis #USH2A https://t.co/kUDLVCk7yC
-
-
Mashup Score: 4Amaros closes Series A financing, forms advisory board - 17 day(s) ago
Funding will support continued product development, while the board is composed of “global leaders in posterior and anterior segment eye care, artificial intelligence and clinical trial design.”
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Amaros has announced the successful closing of Series A financing, backed by “a select group of new and existing mission-aligned investors.” https://t.co/aVMmM64dxN
-
Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study (NCT06962839). THULITE will evaluate the efficacy, safety, and tolerability of BI 1815368, an oral medication for the treatment of diabetic macular edema (DME). https://t.co/KT61GSD1gj